Oxygen as an Acute Treatment in Alternating Hemiplegia of Childhood

Alternating Hemiplegia of Childhood Clinical Trial

— OXYTAHANE  

Official title:

Oxygen Therapy as an Acute Treatment for Dystonic and/or Plegic Attacks in Alternating Hemiplegia of Childhood

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06248645
• Other study ID #: APHP230673
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 2024
• Est. completion date: March 2025

Study information

• Verified date: February 2024
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Emmanuel Flamand-Roze, MD, PhD
• Phone: 0142162748
• Email: flamand.roze.75012[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Alternating hemiplegia of childhood (AHC) is a rare early-onset neurodevelopmental encephalopathy frequently caused by mutations in the ATP1A3 gene. It is typically characterized by a variable degree of intellectual disability, motor dysfunction and various paroxysmal events (dystonic and plegic attacks). Dystonic and plegic attacks are very disabling and current treatments are disappointing with limited efficacy and poor tolerability. The investigators recently reported the efficacy of high-flow oxygen administration (100% O2 at a flow rate of 12 L/min) as an acute treatment for the dystonic attacks in a 25-year-old patient suffering from AHC. The aim of the study is to assess the effect of high-flow oxygen administration (against placebo) as an acute treatment of dystonic and plegic attacks. The primary outcome will be the proportion of motor attacks stopped 30 minutes after the beginning of motor symptoms over 5 weeks.

Description:

This is a multicenter, randomized, placebo-controlled, double-blind crossover study, with two successive periods of 5 weeks.

Participants will be randomized in a 1:1 ratio to receive one of the two treatment sequences:

oxygen followed by placebo or placebo followed by oxygen. The two treatment periods will be separated by a wash-out period of 10 days +/- 4 days.

The placebo will consist in the administration of medical air. The same procedure will be used for both treatments (oxygen and medical air): administration with a flow rate of 12 L/min through a non-rebreathing facial mask using indiscernible bottles.

The treatment will be administered as soon as possible after the beginning of the attack and for 15 minutes. If the attack hasn't stopped 30 minutes after the beginning of motor symptoms, the patients will be allowed to receive their usual acute pharmacological treatment if they (or their caregiver) judge it necessary.

The primary outcome will be the proportion of motor attacks stopped 30 minutes after the beginning of motor symptoms over 5 weeks. The secondary outcomes will be:

1. the median duration of dystonic and plegic attacks over 5 weeks

2. the evaluation of the quality of life for patients (PELHS-QOL-2) and caregivers (adapted from the PELHS-QOL-2) at the end of the 5 weeks of treatment

3. the frequency of motor attacks over 5 weeks

4. the consumption of sedative treatments over 5 weeks (number of doses used)

5. treatment tolerance, in particular mouth and nasal dryness, cutaneous irritation, cough, nasal congestion, nausea, other unexpected side effects

6. the proportion of dystonic and plegic attacks respectively stopped 30 minutes after the beginning of motor symptoms over 5 weeks

7. the number and proportion of treated attacks over 5 weeks

8. the number and proportion of attacks starting less than 2 hours after the end of the previous attack

9. the duration of the first attack for each of the two periods of treatment

10. the perception of patients and caregivers at the end of the 5 weeks of treatment, assessed with recorded interviews

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

1. Age > 1 year old

2. Patients able to administrate high-flow oxygen through a non rebreathing facial mask, either alone or with assistance

3. Patients with a diagnosis of AHC caused by ATP1A3 mutations presenting at least one dystonic or plegic attack per week lasting more than 30 minutes

4. Absence of long-term treatment or long-term treatment stable over the last month and during the duration of the trial

5. Patients able to give written informed consent

6. Affiliation to social insurance

Exclusion Criteria:

1. Inability for the patients and/or caregivers to follow the protocol (inability to read or understand the instructions, no access to smartphone or computer to fill the informatics patient's form)

2. Patients with severe or uncontrolled obstructive or restrictive chronic respiratory disease (asthma, COPD, obesity, neuromuscular disease), acute systemic aggression (acute coronary syndrome, stroke, sepsis, head trauma) or congenital cardiopathy with a risk of hypercapnia following oxygen administration

3. Women that are pregnant (a negative pregnancy test is required for inclusion) or breath feeding

4. Patients involved in an other clinical trial

Related Conditions & MeSH terms

• Alternating Hemiplegia of Childhood
• Hemiplegia

Intervention

Drug:
• Oxygen
High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
• Placebo
High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.

Locations

Country	Name	City	State
France	HCL LYON	Lyon
France	Hôpital Pitié Salpêtrière	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of motor attacks stopped 30 minutes after the beginning of motor symptoms over 5 weeks.	The primary outcome will be the proportion of motor attacks stopped 30 minutes after the beginning of motor symptoms over 5 weeks.	5 weeks
Secondary	the median duration of dystonic and plegic attacks over 5 weeks		5 weeks
Secondary	the evaluation of the quality of life for patients (PELHS-QOL-2 Pediatric Epilepsy Learning Healthcare System Quality of Liferated, from 2 to 8) and caregivers (adapted from the PELHS-QOL-2) at the end of the 5 weeks of treatment		5 weeks
Secondary	the frequency of motor attacks over 5 weeks		5 weeks
Secondary	the consumption of sedative treatments over 5 weeks (number of doses used)		5 weeks
Secondary	treatment tolerance, in particular mouth and nasal dryness, cutaneous irritation, cough, nasal congestion, nausea, other unexpected side effects		5 weeks
Secondary	the proportion of dystonic and plegic attacks respectively stopped 30 minutes after the beginning of motor symptoms over 5 weeks		5 weeks
Secondary	the number and proportion of attacks starting less than 2 hours after the end of the previous attack		5 weeks
Secondary	the duration of the first attack for each of the two periods of treatment		5 weeks
Secondary	the perception of patients and caregivers at the end of the 5 weeks of treatment, assessed with recorded interviews		5 weeks